Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Journal of Heart Failure

• Publication date

  2011-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/eurjhf/hfq212PMID 21169387
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eplerenone in patients with systolic heart failure and mild symptoms.

  2011cited by this paper
• Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

  2010cited by this paper
• Heart disease and stroke statistics--2010 update: a report from the American Heart Association.

  2010cited by this paper
• Executive summary: heart disease and stroke statistics--2010 update: a report from the American Heart Association.

  2010cited by this paper
• Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial.

  2009cited by this paper
• A graphical approach to sequentially rejective multiple test procedures

  2009cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 ‡

  2008cited by this paper
• Telmisartan, ramipril, or both in patients at high risk for vascular events.

  2008cited by this paper
• Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure

  2008cited by this paper
• Absorption, Distribution, Metabolism, and Elimination of the Direct Renin Inhibitor Aliskiren in Healthy Volunteers

  2007influential reference
• Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure

  2007cited by this paper
• The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.

  2004cited by this paper
• Structure-based design of aliskiren, a novel orally effective renin inhibitor.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

  2003cited by this paper
• Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT)

  2003cited by this paper
• Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril.

  2002cited by this paper
• BNP and congestive heart failure.

  2002cited by this paper
• Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril

  2002cited by this paper
• A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.

  2001cited by this paper
• Prothrombotic effects of angiotensin.

  2000cited by this paper
• Angiotensin II receptor antagonists.

  2000cited by this paper
• Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system.

  1998cited by this paper
• Current concepts in the treatment of congestive heart failure.

  1997cited by this paper
• Overview of Randomized Trials of Angiotensin-Converting Enzyme Inhibitors on Mortality and Morbidity in Patients With Heart Failure

  1995cited by this paper
• [Angiotensin II receptor antagonists].

  1995cited by this paper
• Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials.

  1995cited by this paper
• Cough and inhibition of the renin-angiotensin system.

  1993cited by this paper
• Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.

  1992cited by this paper
• A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure.

  1991influential reference
• Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.

  1991cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1988cited by this paper
• Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

  1987cited by this paper
• Current concepts in the treatment of congestive heart failure.

  1984cited by this paper

• European Journal of Heart Failure consensus statement. Heart failure pharmacotherapy for patients with heart failure with reduced ejection fraction and concomitant atrial fibrillation: Review of evidence and call to action

  2025cites this paper
• Designing trials with multiple objectives with graphical approach for multiple scenarios

  2025cites this paper
• Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON‐HF Proteomic Substudy

  2024cites this paper
• Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM‐HF and ATMOSPHERE

  2023cites this paper
• Independent prognostic importance of blood urea nitrogen to creatinine ratio in heart failure

  2023cites this paper
• The First Dedicated Comprehensive Heart Failure Program in the US: the Division of Circulatory Physiology at Columbia Presbyterian (1992-2004).

  2023cites this paper
• Reverse graphical approaches for multiple test procedures

  2023cites this paper
• Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation

  2022cites this paper
• Aptamer Proteomics for Biomarker Discovery in Heart Failure with Reduced Ejection Fraction

  2022cites this paper
• [Predictive value of QRS complex duration in patients with chronic heart failure and atrial fibrillation: retrospective study].

  2022cites this paper
• Natriuretic Peptide Plasma Concentrations and Risk of Cardiovascular Versus Non-Cardiovascular Events in Heart Failure with Reduced Ejection Fraction Insights from the PARADIGM-HF and ATMOSPHERE Trials.

  2021cites this paper
• Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews

  2020cites this paper
• Prevalence and incidence of intra‐ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE

  2020cites this paper
• Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure.

  2020cites this paper
• Graphical approaches for the control of generalized error rates

  2020influential citation
• The Renin-Angiotensin-Aldosterone System: Genomics, Proteomics and Therapeutic Implications

  2019cites this paper
• Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction

  2019cites this paper
• Medikamenten-resistente Herzinsuffizienz

  2019cites this paper
• Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the ATMOSPHERE trial

  2018cites this paper
• Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas

  2018cites this paper
• Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction.

  2017cites this paper
• Dual RAAS Blockade with Aliskiren in Patients with Severely Impaired Chronic Kidney Disease.

  2017cites this paper
• Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation

  2017cites this paper
• New pharmacological approaches in heart failure therapy: developments and possibilities.

  2017cites this paper
• Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure.

  2016cites this paper
• Medical therapy of heart failure with reduced ejection fraction: current evidence and new developments.

  2016cites this paper
• In memoriam Henry Krum, 1958-2015

  2016cites this paper
• Global cardiovascular protection in chronic kidney disease

  2016cites this paper
• New Targets in the Drug Treatment of Heart Failure

  2016cites this paper
• Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.

  2016cites this paper
• Pharmacological interventions for heart failure in people with chronic kidney disease.

  2016cites this paper
• Cardiovascular and Renal Outcomes of Renin–Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses

  2016cites this paper
• Challenges to Data Monitoring Committees When Regulatory Authorities Intervene.

  2016cites this paper
• Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies

  2016cites this paper
• Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria

  2015cites this paper
• The EJHF last Editor's legacy: how can a high impact factor be built?

  2015cites this paper
• Bioactive Compounds in Canola Meal

  2015cites this paper
• zur Erlangung des akademischen Grades Doctor medicinae (Dr. med.)

  2015influential citation
• Too much is too much: evidence against dual RAAS inhibition in hypertensives with heart failure symptoms.

  2015cites this paper
• Evaluation of a rapid method for the therapeutic drug monitoring of aliskiren, enalapril and its active metabolite in plasma and urine by UHPLC-MS/MS.

  2015cites this paper
• Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.

  2015cites this paper
• Heart failure: a major management challenge with encouraging recent progress.

  2015cites this paper
• Outpatient management of chronic heart failure

  2015cites this paper
• Practical approaches for the treatment of chronic heart failure: Frequently asked questions, overlooked points and controversial issues in current clinical practice.

  2015cites this paper
• The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics

  2015cites this paper
• New medical therapies for heart failure

  2015cites this paper
• Альманах-2013: cерцева недостатність *

  2014cites this paper
• ESC National Societies Cardiovascular Journals EditorsNetwork

  2014cites this paper
• Hypertension-induced inflammation: from cellular mechanisms to disease

  2014cites this paper
• Newest additions to heart failure treatment

  2014influential citation
• Reperfusion and Vasodilator Therapy in Elderly Patients with STEMI and Heart Failure: Improving Outcomes

  2014cites this paper
• The RAAS in Heart Failure: An Update on Clinical Trials and Opportunities for Therapy

  2014cites this paper
• Effects of a Long-Term Treatment With Aliskiren or Ramipril on Structural Alterations of Subcutaneous Small-Resistance Arteries of Diabetic Hypertensive Patients

  2014cites this paper
• Increasing complexity: which drug class to choose for treatment of hypertension in the elderly?

  2014cites this paper
• Aging and Remodeling of the RAS and RAAS and Related Pathways: Implications for Heart Failure Therapy

  2014cites this paper
• A note on testing families of hypotheses using graphical procedures

  2014influential citation
• [Risks of dual blockade of the renin-angiotensin system compared with monotherapy: a systematic review and cumulative meta-analysis of randomized trials and observational studies].

  2014cites this paper
• Effect Modification of Interventions. Bridging the Gap Between Clinical Studies and the Individual Patient

  2014cites this paper
• Graphical Approaches to Multiple Testing

  2014cites this paper
• Bloqueo dual del sistema renina-angiotensina frente a la monoterapia: revisión sistemática y metaanálisis acumulativo de ensayos clínicos y estudios observacionales

  2014cites this paper
• Novel Blockers of the Renin-Angiotensin-Aldosterone System in Chronic Heart Failure

  2014influential citation
• A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

  2014cites this paper
• Increasing complexity: which drug class to choose for treatment of hypertension in the elderly?

  2014cites this paper
• Heart failure highlights in 2012–2013

  2014cites this paper
• Increasing complexity: which drug class to choose for treatment of hypertension in the elderly?

  2014cites this paper
• Simultaneous quantitative and qualitative analysis of aliskiren, enalapril and its active metabolite enalaprilat in undiluted human urine utilizing LC-ESI-MS/MS.

  2014cites this paper
• Modulation of the Renin-Angiotensin-Aldosterone System in Heart Failure

  2014cites this paper
• Clinical Implication of the Renin-angiotensin-aldosterone Blockers in Chronic Kidney Disease Undergoing Hemodialysis

  2014cites this paper
• Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure.

  2014cites this paper
• Increasing complexity: which drug class to choose for treatment of hypertension in the elderly?

  2014cites this paper
• The Year in Cardiology 2013: heart failure.

  2014cites this paper
• Almanac 2013: stable coronary artery disease.

  2014cites this paper
• Renin-angiotensin system blockade: time for a reappraisal?

  2014cites this paper
• The Safety and Short-Term Efficacy of Aliskiren in the Treatment of Immunoglobulin A Nephropathy – A Randomized Cross-Over Study

  2013cites this paper
• Almanac 2013: heart failure

  2013cites this paper
• RAAS Inhibitors and Cardiovascular Protection in Large Scale Trials

  2013influential citation
• Pathological Ventricular Remodeling: Mechanisms Part 1 of 2

  2013cites this paper
• Pathological Ventricular Remodeling: Therapies Part 2 of 2

  2013cites this paper
• Complete Renin–Angiotensin–Aldosterone System (RAAS) Blockade in High-Risk Patients: Recent Insights From Renin Blockade Studies

  2013cites this paper
• Diabetes, aliskiren, and heart failure: let's bring ASTRONAUT down to earth.

  2013cites this paper
• Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.

  2013cites this paper
• Almanah 2013.: zatajivanje srca Almanac 2013: heart failure

  2013cites this paper
• Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE

  2013cites this paper
• Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial.

  2013cites this paper
• Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?

  2013cites this paper
• Current strategies for preventing renal dysfunction in patients with heart failure: a heart failure stage approach

  2013cites this paper
• Aliskiren vs. other antihypertensive drugs in the treatment of hypertension: a meta-analysis

  2013cites this paper
• Frontiers of therapy for patients with heart failure.

  2013cites this paper
• Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials

  2013cites this paper
• Review of direct renin inhibition by aliskiren

  2013cites this paper
• [Recent and future innovations in the treatment of heart failure].

  2013cites this paper
• The potential role of valsartan + AHU377 (LCZ696) in the treatment of heart failure

  2013cites this paper
• Targeting the renin–angiotensin–aldosterone system in heart failure

  2013cites this paper
• Renin–Angiotensin–Aldosterone System Inhibitors in Heart Failure

  2013cites this paper
• No increase in adverse events during aliskiren use among ontario patients receiving angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.

  2013cites this paper
• Blood pressure and plasma renin activity responses to different strategies to inhibit the renin-angiotensin-aldosterone system during exercise

  2013cites this paper
• Étude sur le traitement de fond des patients en décompensation cardiaque hospitalisés dans le service de cardiologie de l'hôpital de Langon

  2013cites this paper
• Inovação na abordagem farmacológica da insuficiência cardíaca

  2013cites this paper
• WHAT IS THE PLACE OF ALISKIREN IN THE PRESENT TREATMENT OF ARTERIAL HYPETENSION

  2013cites this paper
• Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial.

  2013cites this paper